Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00763295|
Recruitment Status : Completed
First Posted : September 30, 2008
Last Update Posted : October 26, 2012
HIV infection highly increases the risk of progression of latent tuberculosis (TB) to active disease that therapy is recommended for all PPD-positive, HIV-infected patients, regardless of age. Sensitivity of the PPD testing is, however, dependent on a normal T cell function.
Therefore, an accurate and reliable method for detection of latent tuberculosis in patients with HIV is urgently needed.
This prospective study will examine the utility of interferon-gamma (IFN-γ) based assay, T-SPOT.TB,for detection of TB in HIV-infected individuals.
|Condition or disease||Intervention/treatment|
|Latent Tuberculosis HIV Infections||Other: T-Spot.TB test|
|Study Type :||Observational|
|Actual Enrollment :||53 participants|
|Official Title:||Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?|
|Study Start Date :||May 2008|
|Actual Primary Completion Date :||January 2010|
|Actual Study Completion Date :||January 2010|
Other: T-Spot.TB test
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00763295
|United States, New York|
|Staten Island University Hospital|
|Staten Island, New York, United States, 10305|